Tag Archives: Vertex Pharmaceuticals

Oppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today. The company’s shares closed yesterday at $147.59. According to TipRanks.com, Singh is a 4-star analyst with an average return of 11.3% and a 42.6% success rate.

Cowen & Co. Keeps a Buy Rating on Vertex Pharmaceuticals

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) yesterday and set a price target of $200. The company’s shares opened today at $156.05. According to TipRanks.com, Nadeau is a 5-star analyst with an

Maxim Group Reaffirms Their Buy Rating on Vertex Pharmaceuticals

Maxim Group analyst Jason McCarthy maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today and set a price target of $200. The company’s shares closed yesterday at $158.81. McCarthy commented: “Vertex reported 1Q18 with revenue of $641M, beating consensus

JMP Securities Sticks to Its Hold Rating for Vertex Pharmaceuticals

JMP Securities analyst Liisa Bayko reiterated a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today and set a price target of $211. The company’s shares opened today at $151.40. According to TipRanks.com, Bayko is a 5-star analyst with an average

Oppenheimer Releases a Buy Rating on Vertex Pharmaceuticals

Oppenheimer analyst Hartaj Singh assigned a Buy rating to Vertex Pharmaceuticals (NASDAQ: VRTX) today. The company’s shares opened today at $151.40. According to TipRanks.com, Singh is a 5-star analyst with an average return of 24.7% and a 54.5% success rate.

Vertex Pharmaceuticals Receives a Hold from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX), with a price target of $103. The company’s shares closed yesterday at $152.01. Fein noted: “Halts Triple Combination Trials in France